Iloprost

C5HRO 110-87-2) see Dinoprost Dolasetron mesilate Flomoxef Iloprost Misoprostol Montelukast sodium Orlistat Pirarubicin Saquinavir... 

Ferrari, R, Caigoni, A., Curello, S., Boffa, G.M. and Ceconi, C. (1989). Effects of iloprost (ZK 36374) on glutathione status during ischaemia and reperfusion of isolated rabbit hearts. Br. J. Pharmacol. 98, 678-684. 

Prostacyclin and its analogues also function by increasing the level of platelet cAMP, presumably by activation of the enzyme adenyl cyclase. A chemically stable analogue of prostacyclin called Iloprost has been effective in preventing consumption of platelets (71). 

Idzko M. Hammad H, van Nimwegen M, Kool M, Vos N, Hoogsteden HC, Lambrecht BN Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J Clin Invest 2007 II7 464-472. 

The intra-platelet levels of cAMP can be stabilized by prostacyclin or its analogues (e.g., iloprost) or by dipyridamole. The former activates adenyl cyclase via a G-protein-coupled receptor the latter inhibits a phosphodiesterase that breaks down cAMP. 

Follow the instructions provided by the drug manufacturer for administration of the iloprost dose and maintenance of the Prodose AAD system. 

Mixing with other medications - Direct mixing of iloprost with other medications in the Prodose AAD system has not been evaluated. 

Alternative treatments Use of iloprost with other approved treatments for pulmonary hypertension has not been studied. If patients deteriorate while on this treatment, consider alternative treatments. 

Pharmacology Iloprost is a synthetic analog of prostacyclin PGl2- Iloprost dilates systemic and pulmonary arterial vascular beds. 

Absorption-The absolute bioavailability of inhaled iloprost has not been determined. Iloprost was generally not detectable in the plasma 30 minutes to 1 hour after inhalation. 

Distribution - Iloprost is approximately 60% protein bound, mainly to albumin. 

Metaboiism/Excretion- Iloprost is metabolized principally via beta-oxidation of the carboxyl side chain. The half-life of iloprost is 20 to 30 minutes. 

Administration Iloprost is intended for inhalation administration only via the Prodose AAD system, a pulmonary drug delivery device. It has not been studied with any other nebulizers. 

Syncope Because of the risk of syncope, monitor vital signs while initiating iloprost. In patients with low systemic blood pressure, take care to avoid further hypotension. Do not initiate iloprost in patients with systolic blood pressure less than 85 mm Hg. Be alert to the presence of concomitant conditions or drugs that might increase the risk of syncope. Syncope can also occur in association with pulmonary arterial hypertension, particularly in association with physical exertion. 

Puimonary edema If signs of pulmonary edema occur when inhaled iloprost is administered in patients with pulmonary hypertension, stop the treatment immediately. This may be a sign of pulmonary venous hypotension. 

Hepatic function impairment Because iloprost elimination is reduced in patients with impaired liver function, exercise caution during iloprost therapy in patients with at least Child-Pugh class B hepatic impairment. 

Lactation It is not known whether iloprost is excreted in human milk. 

Monitoring Because of the risk of syncope, monitor vital signs while initiating iloprost. Do not initiate iloprost in patients with systolic blood pressure less than 85 mm Hg. 

Contact with iioprost soiution Do not allow iloprost solution to come into contact with the skin or eyes avoid oral ingestion of iloprost solution. 

Speciai risk Iloprost has not been studied in patients with pulmonary hypertension, which increases mean AUC in otherwise healthy patients. 

Iloprost has not been evaluated in patients with chronic obstructive pulmonary disease (CORD), severe asthma, or acute pulmonary infections. 

Vasodiiators/Antihypertensive agents Iloprost has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents. 

Anticoaguiants Iloprost inhibits platelet function there is a potential for increased risk of bleeding. 

---